Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
[Feature articles] “Issues on Nucleic Acid and Gene Medicines and DDS Development” Editor:Makiya Nishikawa
Current status and future prospects of virus-based gene medicine
Fuminori Sakurai
Author information
JOURNAL FREE ACCESS

2019 Volume 34 Issue 2 Pages 99-105

Details
Abstract
More than 25 years have passed since the world’s first gene therapy trial for adenosine deaminase deficiency in the United States in 1990. Dramatic therapeutic effects were reported in the several clinical trials, on the other hand, therapeutic effects did not reach anticipated levels in many cases. Furthermore, severe side effects were found in a few clinical trials. Gene therapy suffered a period of winter-like hardship. However, 7 types of gene medicines, including a lipoprotein lipase-expressing adeno-associated virus vector (Glybera) in 2012, has been successively approved afterwards due to the continuous efforts by researchers. Now gene therapy is becoming a reality. In this review, I describe the current status and future prospects of virus-based gene medicines.
Content from these authors
© 2019 The Japan Society of Drug Delivery System
Previous article Next article
feedback
Top